BELGRADE, MT, Feb. 12, 2019 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the recent additions of five senior sales executives: Dana Lyons, Vice President of US Sales, Jamey Rottman, Regional Vice President, Mid Atlantic, Chris Cochran, Regional Vice President, South East, John Eekhof, Regional Vice President, North East, and Luke Armand, Regional Vice President, West. These additions, along with the appointment of Kevin Brandt, as Chief Commercial Officer, in July 2018, bring to the Company over 150 years of combined commercial experience and relationships in the spine industry.
In announcing the team, Kevin Brandt stated, “We are excited to welcome these dedicated and proven sales leaders to our team who will bring strong spine experience and have proven track records in this industry. Appointing these sales leaders demonstrates our commitment to competing in the spine market and leveraging the strength of our full product portfolio. These leaders all have an extended product and therapy knowledge, as well as deep relationships in the commercial spine market, which will provide great value to our customers and shareholders.”
Dana Lyons, Vice President of US Sales
Dana is well known in the medical device industry with 29 years of experience. He has served in various capacities at Biomet, Stryker, and Zimmer Spine, where he was instrumental in the growth of each organization. Most recently, Dana served as Vice President of Sales and Marketing for Amedica where he was able to expand the customer base, improve on the depth and breadth of the sales team, and successfully launch a new modular pedicle screw system to the market.
Jamey Rottman, RVP Sales, Mid-Atlantic Region
Jamey has over 25 years of experience in the spine industry, having worked for Spine Tech, Zimmer, Zimmer Biomet, and most recently Amedica. Jamey has held roles in marketing, sales training, professional education, and market development at the senior leadership level. Jamey has strong knowledge of the spine industry in both hardware and biologics.
Chris Cochran, RVP Sales, South East Region
Chris has over 25 years’ experience in sales and in spine. His skill set includes sales and marketing leadership as well as leading an independent medical device distributorship. Chris recently worked with Amedica as an area vice president where he was instrumental in increasing revenue both organically and following a company acquisition. He has also held leadership roles at Spineart USA, Life Spine, Tissue Banks International and Regeneration Technologies, Inc.
John Eekhof, RVP Sales, North East Region
John has over 25 years’ experience in the spine industry with executive leadership roles in sales and marketing. Most recently, John was a key leader in the international spinal and biologics business at Stryker Spine, with roles in product marketing and marketing communications. Prior to Stryker Spine, John was at Medtronic in various commercial spine leadership roles.
Luke Armand, RVP Sales, West Region
Luke brings over 18 years of combined experience in sales, marketing, product development and sales team development and management. Combined with his experience at Abbott Spine, LDR Spine, and RTI Surgical, he was most recently the regional sales director for North America at Curasan. Luke has a proven record of developing and implementing revenue driving initiatives.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
Cautionary Note Regarding Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘will,” ‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ “continue,” “future,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the expectation that the new senior sales leaders will add great value to our customers and shareholders. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; its ability to increase revenue, remain competitive and innovate and develop new products; the effect of management changes and ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products, ability to obtain and maintain regulatory approvals; government regulations; product liability claims and other litigation to which the Company may be subject; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed with the SEC on November 14, 2018. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Kathie Lenzen, Chief Financial Officer